- SID Score
- 6.2/10
- Fair value
- $509.31
- Generated
- Oct 17, 2026
- Model
- claude-haiku-4-5-20251001
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) is trading at $400.00 with a substantial market capitalization of $1.82 trillion, positioning it as a significant player in the healthcare sector. The stock exhibits a moderate SID Score of 6.2/10 with fair value estimated at $509.31, suggesting 27.3% upside potential. However, the security faces mixed factor grades and limited technical data availability, warranting careful consideration before investment.
The company demonstrates a P/E ratio of 17.28, which is reasonable for the healthcare sector, alongside a minimal dividend yield of 0.05%, indicating limited income generation for shareholders. Factor analysis reveals concerning weakness in value metrics (Grade D) while growth (C), profitability (C), and dividends (B) present moderate performance. The substantial gap between current price and fair value estimate suggests potential undervaluation, though the lack of recent financial and earnings data limits comprehensive fundamental assessment.
Technical analysis capabilities are severely constrained due to unavailable 50-day and 200-day moving averages and RSI(14) data, preventing trend assessment and momentum evaluation. Without these critical indicators, investors cannot determine whether the stock is in an uptrend, downtrend, or consolidation phase. This data limitation significantly hampers the ability to identify optimal entry points or validate price momentum.
Analyst & Insider Sentiment
Analyst consensus remains neutral with no average price target available, providing minimal directional guidance for investors. Recent insider activity shows mixed signals, with Bartie Wendy executing net selling activity (combined 20,121 shares sold versus 15,957 bought) and Lenkowsky Adam selling 21,680 shares on May 1, 2026, suggesting some insider hesitation. These selling transactions by company insiders typically warrant cautious monitoring, though the magnitude relative to total market cap remains modest.
As a convertible preferred security, BMYMP carries hybrid risk characteristics combining equity price volatility with fixed income credit risk, creating complexity for retail investors. The extremely low dividend yield of 0.05% provides minimal downside cushion, and the significant market cap concentration in the healthcare sector exposes investors to regulatory and pharmaceutical industry-specific risks. The absence of recent financial data creates additional uncertainty regarding current operational performance and near-term catalysts.
BMYMP presents a speculative opportunity for investors with a 27.3% upside to fair value, but the weak value grade (D), limited dividend income, and insider selling activities suggest caution is warranted. The convertible preferred structure may appeal to sophisticated investors seeking equity-like upside with some downside protection, yet the neutral analyst consensus and data gaps recommend waiting for clearer technical confirmation or improved sentiment indicators. Conservative investors should require better value metrics and stronger fundamental evidence before initiating positions.
